Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

NCT02568267 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02568267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02568267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 19, 2015
Completion date
June 30, 2027
Enrollment
534 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid tumor, breast cancer, cholangiocarcinoma, colorectal cancer, head and neck neoplasms, lymphoma, large-cell, anaplastic, melanoma, neuroendocrine tumors, non-small cell lung cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer, primary brain tumors, renal cell carcinoma, salivary gland cancers, sarcomas